A COST-CONSEQUENCE ANALYSIS OF PONATINIB VERSUS IMATINIB IN PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA IN THE UNITED STATES

被引：0
|
作者：
Hernandez, L. G. [1 ]
Davies, S. [2 ]
Li, C. [3 ]
Reddick, L. E. [1 ]
Jensen, I [2 ]
机构：
[1] Takeda Pharmaceut Amer Inc, Lexington, MA USA
[2] PRECISIONheor, Precis Value & Hlth, Boston, MA USA
[3] Takeda Dev Ctr Amer Inc, Lexington, MA USA
来源：
VALUE IN HEALTH | 2024年 / 27卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE165
引用
收藏
页码：S88 / S88
页数：1
相关论文
共 50 条
  • [1] Nilotinib combined with multiagent chemotherapy for newly diagnosed Philadelphia-positive acute lymphoblastic leukemia
    Kim, Dae-Young
    Joo, Young-Don
    Lim, Sung-Nam
    Kim, Sung-Doo
    Lee, Jung-Hee
    Lee, Je-Hwan
    Kim, Dong Hwan
    Kim, Kihyun
    Jung, Chul Won
    Kim, Inho
    Yoon, Sung-Soo
    Park, Seonyang
    Ahn, Jae-Sook
    Yang, Deok-Hwan
    Lee, Je-Jung
    Lee, Ho-Sup
    Kim, Yang Soo
    Mun, Yeung-Chul
    Kim, Hawk
    Park, Jae Hoo
    Moon, Joon Ho
    Sohn, Sang Kyun
    Lee, Sang Min
    Lee, Won Sik
    Kim, Kyoung Ha
    Won, Jong-Ho
    Hyun, Myung Soo
    Park, Jinny
    Lee, Jae Hoon
    Shin, Ho-Jin
    Chung, Joo-Seop
    Lee, Hyewon
    Eom, Hyeon-Seok
    Lee, Gyeong Won
    Cho, Young-Uk
    Jang, Seongsoo
    Park, Chan-Jeoung
    Chi, Hyun-Sook
    Lee, Kyoo-Hyung
    BLOOD, 2015, 126 (06) : 746 - 756
  • [2] Efficacy of Ponatinib Versus Earlier Generation Tyrosine Kinase Inhibitors for Front-line Treatment of Newly Diagnosed Philadelphia-positive Acute Lymphoblastic Leukemia
    Jabbour, Elias
    DerSarkissian, Maral
    Duh, Mei Sheng
    McCormick, Nora
    Cheng, Wendy Y.
    McGarry, Lisa J.
    Souroutzidis, Ariadne
    Huang, Hui
    O'Brien, Susan
    Ravandi, Farhad
    Kantarjian, Hagop M.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 (04): : 257 - 265
  • [3] Imatinib Treatment Alone in Philadelphia-Positive Acute Lymphoblastic Leukemia: Is It Enough?
    Ay, Yilmaz
    Yilmaz, Deniz
    Balkan, Can
    Karapinar, Bulent
    Karadas, Nihal
    Kavakli, Kaan
    CASE REPORTS IN ONCOLOGY, 2011, 4 (02): : 323 - 326
  • [4] Ponatinib Versus Imatinib with Reduced-Intensity Chemotherapy in Patients with Newly Diagnosed Philadelphia Chromosome-Positive (Ph plus ) Acute Lymphoblastic Leukemia (ALL): PhALLCON Study
    Jabbour, Elias
    Martinelli, Giovanni
    Vignetti, Marco
    Kantarjian, Hagop
    Gomez-Almaguer, David
    Minami, Yosuke
    Dombret, Herve
    Hennessy, Meliessa
    Vorog, Alexander
    Wang, Bingxia
    Ribera, Josep-Maria
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S269 - S269
  • [5] Severe skin reaction to imatinib in a case of Philadelphia-positive acute lymphoblastic leukemia
    Sanchez-Gonzalez, B
    Pascual-Ramirez, JC
    Fernandez-Abellan, P
    Belinchon-Romero, I
    Rivas, C
    Vegara-Aguilera, G
    BLOOD, 2003, 101 (06) : 2446 - 2446
  • [6] Ponatinib vs Imatinib in Frontline Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
    Jabbour, Elias
    Kantarjian, Hagop M.
    Aldoss, Ibrahim
    Montesinos, Pau
    Leonard, Jessica T.
    Gomez-Almaguer, David
    Baer, Maria R.
    Gambacorti-Passerini, Carlo
    McCloskey, James
    Minami, Yosuke
    Papayannidis, Cristina
    Rocha, Vanderson
    Rousselot, Philippe
    Vachhani, Pankit
    Wang, Eunice S.
    Wang, Bingxia
    Hennessy, Meliessa
    Vorog, Alexander
    Patel, Niti
    Yeh, Tammie
    Ribera, Jose-Maria
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2024, 331 (21): : 1814 - 1823
  • [7] Imatinib given concurrently with induction chemotherapy is superior to imatinib subsequent to induction and consolidation in newly diagnosed Philadelphia-positive acute lymphoblastic leukemia (PH plus ALL).
    Ottmann, OG
    Wassmann, B
    Pfeifer, H
    Goekbuget, N
    Bug, G
    Brueck, P
    Binckebanck, A
    Gschaidmeier, H
    Hoelzer, D
    BLOOD, 2004, 104 (11) : 197A - 197A
  • [8] Ponatinib and Blinatumomab for Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Subgroup Analysis from a Phase II Study
    Short, Nicholas
    Kantarjian, Hagop
    Jain, Nitin
    Huang, Xuelin
    Montalban-Bravo, Guillermo
    Kadia, Tapan M.
    Daver, Naval
    Chien, Kelly S.
    Alvarado, Yesid
    Garcia-Manero, Guillermo
    Issa, Ghayas C.
    Macaron, Walid
    Haddad, Fadi
    Kwari, Monica
    Delumpa, Ricardo
    Mayor, Ejiroghene
    Deen, Wuliamatu
    Thankachan, Jennifer
    Loiselle, Christopher
    Rivera, Juan
    Milton, Anna
    Waller, Lourdes
    Banks, Glenda
    Garris, Rebecca
    Konopleva, Marina
    Ravandi, Farhad
    Jabbour, Elias
    BLOOD, 2022, 140
  • [9] Hypoprotidemia May Explain Imatinib Intoxication in a Patient with Philadelphia-positive Acute Lymphoblastic Leukemia
    Gaies, Emna
    Trabelsi, Sameh
    Sahnoun, Rim
    Salouage, Issam
    Jebabli, Nadia
    Charfi, Rim
    Lakhal, Mohamed
    Hdiji, Sonia
    Klouz, Anis
    THERAPIE, 2013, 68 (02): : 125 - 127
  • [10] Clinical Efficacy of Ponatinib in Philadelphia-Positive T-Cell Acute Lymphoblastic Leukemia with Extramedullary Involvement
    Cristiano, Gianluca
    Nanni, Jacopo
    Sartor, Chiara
    Parisi, Sarah
    Marconi, Giovanni
    Barbato, Francesco
    Arpinati, Mario
    Bonifazi, Francesca
    Curti, Antonio
    Cavo, Michele
    Paolini, Stefania
    Papayannidis, Cristina
    ACTA HAEMATOLOGICA, 2021, 144 (06) : 688 - 692
12345